**Core Concept**
Secukinumab is a fully human monoclonal antibody that targets interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of various autoimmune and inflammatory diseases. By inhibiting IL-17A, secukinumab reduces inflammation and modulates the immune response.

**Why the Correct Answer is Right**
Secukinumab is specifically used in the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It has been shown to improve symptoms and quality of life in patients with these conditions by reducing inflammation and slowing disease progression. Secukinumab works by binding to IL-17A, preventing it from interacting with its receptor, and thereby inhibiting the downstream signaling pathways that lead to inflammation and tissue damage.

**Why Each Wrong Option is Incorrect**
**Option A:** While secukinumab is used in psoriatic arthritis, it is not primarily used in the treatment of rheumatoid arthritis, which is typically treated with a different class of biologic agents, such as TNF-alpha inhibitors.
**Option B:** Secukinumab is not used in the treatment of asthma, which is typically treated with inhaled corticosteroids and bronchodilators.
**Option C:** Secukinumab is not used in the treatment of Crohn's disease, which is typically treated with aminosalicylates, corticosteroids, and immunomodulators.

**Clinical Pearl / High-Yield Fact**
Secukinumab is an example of a biologic agent that targets a specific cytokine involved in the pathogenesis of autoimmune and inflammatory diseases. This class of medications has revolutionized the treatment of various chronic conditions by providing targeted and effective therapies.

**Correct Answer: D.**